Literature DB >> 2545347

Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells.

H Ura1, R D Bonfil, R Reich, R Reddel, A Pfeifer, C C Harris, A J Klein-Szanto.   

Abstract

In a series of immortalized human bronchial epithelial cell lines continuing various oncogenes, the transcriptional levels of the type IV collagenase and the type IV procollagen genes were compared with the properties of invasiveness in vitro and tumorigenicity and metastatic ability in athymic nude mice. v-Ha-ras greatly enhanced invasion and metastasis, whereas v-Ki-ras, c-myc, and c-raf had lesser effects on these malignant phenotypes. In addition, cell lines derived from tumors obtained by injecting the original immortalized human bronchial epithelial cell lines into nude mice exhibited enhanced invasive and metastatic abilities and increased level of type IV collagenase mRNA when compared with the original immortalized human bronchial epithelial cell lines. Invasiveness and metastatic capacity correlated positively with expression of the type IV collagenase gene and negatively with the expression of the type IV procollagen gene, suggesting that these phenotypes are associated both with decreased production and increased dissolution of extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545347

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Regulation of keratin and integrin gene expression in cancer and drug resistance.

Authors:  N Daly; P Meleady; D Walsh; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines.

Authors:  M Polette; C Gilles; S de Bentzmann; D Gruenert; J M Tournier; P Birembaut
Journal:  Clin Exp Metastasis       Date:  1998-02       Impact factor: 5.150

Review 3.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

4.  Ovarian cancer cell invasion is inhibited by paclitaxel.

Authors:  A Westerlund; E Hujanen; M Höyhtyä; U Puistola; T Turpeenniemi-Hujanen
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

5.  Oncogene-induced basement membrane invasiveness in human mammary epithelial cells.

Authors:  E W Thompson; J Torri; M Sabol; C L Sommers; S Byers; E M Valverius; G R Martin; M E Lippman; M R Stampfer; R B Dickson
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

6.  Density-dependent induction of 92-kd type IV collagenase activity in cultures of A431 human epidermoid carcinoma cells.

Authors:  B Xie; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

7.  Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNA.

Authors:  Hu Huang; Yi-de Hu; Na Li; Yong Zhu
Journal:  Oligonucleotides       Date:  2009-06

8.  Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines.

Authors:  J Caamano; B Ruggeri; S Momiki; A Sickler; S Y Zhang; A J Klein-Szanto
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

9.  Caffeic acid phenethyl ester inhibits invasion and expression of matrix metalloproteinase in SK-Hep1 human hepatocellular carcinoma cells by targeting nuclear factor kappa B.

Authors:  Ki Won Lee; Nam Joo Kang; Jong Hun Kim; Kyoung Mi Lee; Dong Eun Lee; Haeng Jeon Hur; Hyong Joo Lee
Journal:  Genes Nutr       Date:  2008-02       Impact factor: 5.523

10.  Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays.

Authors:  S N Bae; G Arand; H Azzam; P Pavasant; J Torri; T L Frandsen; E W Thompson
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.